Mark Jeffrey De Long Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Mark Jeffrey De Long is Chief Business & Strat Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 83,945 shares of APLS, which is worth approximately $2.3 Million. The most recent transaction as insider was on Aug 08, 2022, when has been sold 5,000 shares (Common Stock) at a price of $64.5 per share, resulting in proceeds of $322,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 83.9K

38.99% 3M change

29.93% 12M change

Total Value Held $2.3 Million

Mark Jeffrey DeLong Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 08 2022	SELL Open market or private sale	$322,500 $64.5 p/Share	5,000 Reduced 14.6%	29,250 Common Stock
Aug 08 2022	BUY Exercise of conversion of derivative security	$77,600 $15.52 p/Share	5,000 Added 12.74%	34,250 Common Stock
Aug 04 2022	SELL Open market or private sale	$607,500 $60.75 p/Share	10,000 Reduced 25.48%	29,250 Common Stock
Aug 04 2022	BUY Exercise of conversion of derivative security	$155,200 $15.52 p/Share	10,000 Added 20.3%	39,250 Common Stock
Jul 27 2022	SELL Open market or private sale	$285,000 $57.0 p/Share	5,000 Reduced 14.6%	29,250 Common Stock
Jul 27 2022	BUY Exercise of conversion of derivative security	$77,600 $15.52 p/Share	5,000 Added 12.74%	34,250 Common Stock
Jul 19 2022	SELL Open market or private sale	$282,100 $56.42 p/Share	5,000 Reduced 14.6%	29,250 Common Stock
Jul 19 2022	BUY Exercise of conversion of derivative security	$77,600 $15.52 p/Share	5,000 Added 12.74%	34,250 Common Stock
Jun 16 2022	SELL Open market or private sale	$417,800 $41.78 p/Share	10,000 Reduced 25.48%	29,250 Common Stock
Jun 16 2022	BUY Exercise of conversion of derivative security	$138,500 $13.85 p/Share	10,000 Added 20.3%	39,250 Common Stock
Apr 20 2022	SELL Open market or private sale	$367,710 $52.53 p/Share	7,000 Reduced 19.73%	28,481 Common Stock
Apr 20 2022	BUY Exercise of conversion of derivative security	$108,640 $15.52 p/Share	7,000 Added 16.48%	35,481 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$12,770 $47.12 p/Share	271 Reduced 1.14%	23,580 Common Stock
Feb 10 2022	BUY Grant, award, or other acquisition	-	4,901 Added 14.68%	28,481 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$16,748 $38.59 p/Share	434 Reduced 2.07%	20,530 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	10,592 Added 33.57%	20,964 Common Stock
Oct 20 2021	BUY Grant, award, or other acquisition	-	882 Added 7.84%	10,372 Common Stock
Jul 21 2021	SELL Open market or private sale	$65,000 $65.0 p/Share	1,000 Reduced 9.53%	9,490 Common Stock
Jul 21 2021	BUY Exercise of conversion of derivative security	$15,520 $15.52 p/Share	1,000 Added 8.7%	10,490 Common Stock
Jul 15 2021	SELL Open market or private sale	$62,300 $62.3 p/Share	1,000 Reduced 9.53%	9,490 Common Stock
Jul 15 2021	BUY Exercise of conversion of derivative security	$15,520 $15.52 p/Share	1,000 Added 8.7%	10,490 Common Stock
Jun 15 2021	SELL Open market or private sale	$259,840 $64.96 p/Share	4,000 Reduced 29.65%	9,490 Common Stock
Jun 15 2021	BUY Exercise of conversion of derivative security	$62,080 $15.52 p/Share	4,000 Added 22.87%	13,490 Common Stock
May 18 2021	SELL Open market or private sale	$110,000 $55.0 p/Share	2,000 Reduced 17.41%	9,490 Common Stock
May 18 2021	BUY Exercise of conversion of derivative security	$31,040 $15.52 p/Share	2,000 Added 14.83%	11,490 Common Stock

MJD

Mark Jeffrey De Long

Chief Business & Strat Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account